Loading...

We've got a brand new version of Simply Wall St! Try it out

Straumann Holding

SWX:STMN
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
STMN
SWX
CHF14B
Market Cap
  1. Home
  2. CH
  3. Healthcare
Company description

Straumann Holding AG provides tooth replacement solutions worldwide. The last earnings update was 92 days ago. More info.


Add to Portfolio Compare Print
STMN Share Price and Events
7 Day Returns
1.1%
SWX:STMN
0.7%
CH Medical Equipment
-0.4%
CH Market
1 Year Returns
39.8%
SWX:STMN
33.3%
CH Medical Equipment
12.3%
CH Market
STMN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Straumann Holding (STMN) 1.1% 4.3% 14.5% 39.8% 148% 267.1%
CH Medical Equipment 0.7% 2.5% 4.3% 33.3% 85.6% 109.4%
CH Market -0.4% 2.6% 6.7% 12.3% 21.5% 13.4%
1 Year Return vs Industry and Market
  • STMN outperformed the Medical Equipment industry which returned 33.3% over the past year.
  • STMN outperformed the Market in Switzerland which returned 12.3% over the past year.
Price Volatility
STMN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Straumann Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Straumann Holding to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Straumann Holding.

SWX:STMN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 17 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.6%
Perpetual Growth Rate 10-Year CH Government Bond Rate 3.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:STMN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate 3.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.84
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.84 (1 + (1- 18%) (1.76%))
0.901
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.9
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (0.901 * 5.96%)
8.64%

Discounted Cash Flow Calculation for SWX:STMN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Straumann Holding is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SWX:STMN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CHF, Millions) Source Present Value
Discounted (@ 8.64%)
2020 339.04 Analyst x10 312.06
2021 425.89 Analyst x9 360.81
2022 585.00 Analyst x2 456.18
2023 665.00 Analyst x2 477.30
2024 726.38 Est @ 9.23% 479.88
2025 780.46 Est @ 7.44% 474.58
2026 828.79 Est @ 6.19% 463.87
2027 872.86 Est @ 5.32% 449.67
2028 913.93 Est @ 4.7% 433.37
2029 953.01 Est @ 4.28% 415.94
Present value of next 10 years cash flows CHF4,323.00
SWX:STMN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CHF953.01 × (1 + 3.28%) ÷ (8.64% – 3.28%)
CHF18,330.87
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CHF18,330.87 ÷ (1 + 8.64%)10
CHF8,000.51
SWX:STMN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CHF4,323.00 + CHF8,000.51
CHF12,323.51
Equity Value per Share
(CHF)
= Total value / Shares Outstanding
= CHF12,323.51 / 15.83
CHF778.32
SWX:STMN Discount to Share Price
Calculation Result
Value per share (CHF) From above. CHF778.32
Current discount Discount to share price of CHF898.20
= -1 x (CHF898.20 - CHF778.32) / CHF778.32
-15.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Straumann Holding is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Straumann Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Straumann Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:STMN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CHF CHF18.25
SWX:STMN Share Price ** SWX (2019-11-13) in CHF CHF898.2
Switzerland Medical Equipment Industry PE Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 33.29x
Switzerland Market PE Ratio Median Figure of 171 Publicly-Listed Companies 19.37x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Straumann Holding.

SWX:STMN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:STMN Share Price ÷ EPS (both in CHF)

= 898.2 ÷ 18.25

49.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Straumann Holding is overvalued based on earnings compared to the CH Medical Equipment industry average.
  • Straumann Holding is overvalued based on earnings compared to the Switzerland market.
Price based on expected Growth
Does Straumann Holding's expected growth come at a high price?
Raw Data
SWX:STMN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 49.23x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts
16.6%per year
Switzerland Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.34x
Switzerland Market PEG Ratio Median Figure of 124 Publicly-Listed Companies 2.14x

*Line of best fit is calculated by linear regression .

SWX:STMN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 49.23x ÷ 16.6%

2.97x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Straumann Holding is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Straumann Holding's assets?
Raw Data
SWX:STMN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CHF CHF78.55
SWX:STMN Share Price * SWX (2019-11-13) in CHF CHF898.2
Switzerland Medical Equipment Industry PB Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 6.21x
Switzerland Market PB Ratio Median Figure of 214 Publicly-Listed Companies 1.65x
SWX:STMN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:STMN Share Price ÷ Book Value per Share (both in CHF)

= 898.2 ÷ 78.55

11.44x

* Primary Listing of Straumann Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Straumann Holding is overvalued based on assets compared to the CH Medical Equipment industry average.
X
Value checks
We assess Straumann Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Straumann Holding has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Straumann Holding expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Straumann Holding expected to grow at an attractive rate?
  • Straumann Holding's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
  • Straumann Holding's earnings growth is expected to exceed the Switzerland market average.
  • Straumann Holding's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:STMN Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:STMN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts 16.6%
SWX:STMN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts 12.2%
Switzerland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 38.7%
Switzerland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 9.9%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:STMN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:STMN Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 2,565 696 615 3
2022-12-31 2,306 612 548 4
2021-12-31 2,069 528 475 15
2020-12-31 1,833 451 406 17
2019-12-31 1,595 362 325 16
2019-11-14
SWX:STMN Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2019-06-30 1,462 301 289
2019-03-31 1,413 289 281
2018-12-31 1,364 277 273
2018-09-30 1,307 262 271
2018-06-30 1,250 246 269
2018-03-31 1,181 232 274
2017-12-31 1,112 217 280
2017-09-30 1,056 206 257
2017-06-30 1,000 194 235
2017-03-31 959 189 232
2016-12-31 918 185 230
2016-09-30 889 188 218

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Straumann Holding's earnings are expected to grow by 16.6% yearly, however this is not considered high growth (20% yearly).
  • Straumann Holding's revenue is expected to grow by 12.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:STMN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below

All data from Straumann Holding Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:STMN Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 40.24 42.65 37.83 2.00
2022-12-31 35.08 37.23 33.69 3.00
2021-12-31 30.17 31.95 27.33 11.00
2020-12-31 25.68 27.39 24.31 13.00
2019-12-31 20.40 21.89 19.07 13.00
2019-11-14
SWX:STMN Past Financials Data
Date (Data in CHF Millions) EPS *
2019-06-30 18.25
2019-03-31 17.74
2018-12-31 17.24
2018-09-30 17.18
2018-06-30 17.13
2018-03-31 17.58
2017-12-31 18.04
2017-09-30 16.63
2017-06-30 15.21
2017-03-31 14.94
2016-12-31 14.68
2016-09-30 13.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Straumann Holding is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Straumann Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Straumann Holding has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Straumann Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Straumann Holding's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Straumann Holding has delivered over 20% year on year earnings growth in the past 5 years.
  • Straumann Holding's 1-year earnings growth is less than its 5-year average (7.3% vs 21.4%)
  • Straumann Holding's earnings growth has exceeded the CH Medical Equipment industry average in the past year (7.3% vs -9.5%).
Earnings and Revenue History
Straumann Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Straumann Holding Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:STMN Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 1,462.14 288.94 734.28
2019-03-31 1,412.85 280.85 707.29
2018-12-31 1,363.56 272.77 680.31
2018-09-30 1,306.85 270.99 652.19
2018-06-30 1,250.14 269.22 624.07
2018-03-31 1,181.12 274.38 592.48
2017-12-31 1,112.10 279.54 560.90
2017-09-30 1,055.90 257.12 544.33
2017-06-30 999.70 234.70 527.76
2017-03-31 958.61 232.15 510.92
2016-12-31 917.52 229.60 494.07
2016-09-30 889.44 218.35 483.47
2016-06-30 861.36 207.11 472.86
2016-03-31 829.98 138.89 458.93
2015-12-31 798.60 70.68 445.01
2015-09-30 774.11 79.13 434.16
2015-06-30 749.62 87.58 423.30
2015-03-31 729.95 122.70 418.15
2014-12-31 710.27 157.83 413.00
2014-09-30 697.27 137.04 415.73
2014-06-30 684.28 116.25 418.46
2014-03-31 682.10 108.73 421.01
2013-12-31 679.92 101.20 423.57
2013-09-30 679.62 73.91 442.73 -11.26
2013-06-30 679.32 46.62 461.89 -22.52
2013-03-31 682.79 42.06 455.56 -11.26
2012-12-31 686.25 37.51 449.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Straumann Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Straumann Holding used its assets more efficiently than the CH Medical Equipment industry average last year based on Return on Assets.
  • Straumann Holding has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Straumann Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Straumann Holding has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Straumann Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Straumann Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Straumann Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Straumann Holding's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Straumann Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Straumann Holding Company Filings, last reported 4 months ago.

SWX:STMN Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 1,249.53 249.29 191.91
2019-03-31 1,249.53 249.29 191.91
2018-12-31 1,204.32 199.86 280.92
2018-09-30 1,204.32 199.86 280.92
2018-06-30 1,090.44 199.80 246.99
2018-03-31 1,090.44 199.80 246.99
2017-12-31 1,077.05 199.75 283.94
2017-09-30 1,077.05 199.75 283.94
2017-06-30 653.30 199.69 140.44
2017-03-31 653.30 199.69 140.44
2016-12-31 633.68 199.63 165.69
2016-09-30 633.68 199.63 165.69
2016-06-30 723.63 199.58 305.51
2016-03-31 723.63 199.58 305.51
2015-12-31 604.97 199.52 319.93
2015-09-30 604.97 199.52 319.93
2015-06-30 564.88 199.47 208.07
2015-03-31 564.88 199.47 208.07
2014-12-31 736.84 199.41 461.58
2014-09-30 736.84 199.41 461.58
2014-06-30 658.99 199.36 339.19
2014-03-31 658.99 199.36 339.19
2013-12-31 631.38 199.30 386.11
2013-09-30 631.38 199.30 386.11
2013-06-30 599.39 0.00 324.06
2013-03-31 599.39 0.00 324.06
2012-12-31 601.66 0.00 141.02
  • Straumann Holding's level of debt (19.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (30.2% vs 19.8% today).
  • Debt is well covered by operating cash flow (121.8%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 31.1x coverage).
X
Financial health checks
We assess Straumann Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Straumann Holding has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Straumann Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.58%
Current annual income from Straumann Holding dividends. Estimated to be 0.85% next year.
If you bought CHF2,000 of Straumann Holding shares you are expected to receive CHF12 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Straumann Holding's pays a lower dividend yield than the bottom 25% of dividend payers in Switzerland (1.85%).
  • Straumann Holding's dividend is below the markets top 25% of dividend payers in Switzerland (3.63%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:STMN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
Switzerland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 163 Stocks 2.9%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.2%
Switzerland Bottom 25% Dividend Yield 25th Percentile 1.8%
Switzerland Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:STMN Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 11.28 2.00
2022-12-31 9.65 3.00
2021-12-31 8.66 15.00
2020-12-31 7.35 17.00
2019-12-31 6.18 17.00
2019-11-14
SWX:STMN Past Annualized Dividends Data
Date (Data in CHF) Dividend per share (annual) Avg. Yield (%)
2019-02-19 5.250 0.637
2018-02-15 4.750 0.694
2017-02-16 4.250 0.740
2016-02-25 4.000 1.080
2015-02-27 3.750 1.347
2014-02-25 3.750 1.767
2013-02-21 3.750 2.503
2012-02-22 3.750 2.937
2012-02-10 3.750 2.373
2011-02-16 3.750 2.094
2011-01-17 3.750 1.617
2010-01-04 3.750 1.583
2009-02-12 3.750 1.714
2009-01-05 3.750 2.090

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Straumann Holding is not paying a notable dividend for Switzerland, therefore no need to check if the payments are stable.
  • Straumann Holding is not paying a notable dividend for Switzerland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Straumann Holding's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Straumann Holding's dividends as it is not paying a notable one for Switzerland.
Future Payout to shareholders
  • No need to calculate the sustainability of Straumann Holding's dividends in 3 years as they are not expected to pay a notable one for Switzerland.
X
Income/ dividend checks
We assess Straumann Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Straumann Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Straumann Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Straumann Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marco Gadola
COMPENSATION CHF3,701,000
AGE 56
TENURE AS CEO 6.6 years
CEO Bio

Mr. Marco Gadola is an Industrial Advisor at EQT since 2019. He has been the Chief Executive Officer at Straumann Holding AG since April 2013 and serves as its Member of Executive Management Board. He served as the Chief Financial Officer and Executive Vice President of Finance Division at Straumann Holding AG from June 2006 to August 2008 and also served as its Executive Vice President of Operations Division until August 2008. Marco Gadola is a Venture Partner of MTIP AG since 2018 and will actively involve in the selection and evaluation of investment opportunities for the MTIP portfolio. He has been Vice Chairman of Calida Holding AG since May 13, 2014 and has been its Director since April 7, 2011. He has been a Director of MCH Group AG since April 22, 2016. He serves as a Director of Luxair S.A., Société Luxembourgeoise de Navigation Aérienne. Mr. Gadola served as the Chief Financial Officer and Member of Executive Board of Panalpina AB since October 2008. He is a seasoned executive with a strong international track record in finance, administration and supply chain management. He served as the Regional Chief Executive Officer of Asia Pacific at Panalpina World Transport Holding Ltd. since 2012 and its Chief Financial Officer from September 2008 to July 41, 2012. Mr. Gadola served as a Member of Executive Board of Panalpina World Transport Holding Ltd. since September 2008. He served as the Chief Financial Officer and Member of Management Board at Hero AG (Hero Schweiz AG) and also served as its Finance Director since September 2001. Mr. Gadola served as Chief Financial Officer of the Swiss-based international food group Hero since 2001 and was responsible for finance, information technology and supply chain. He was also responsible for financial and commercial of several Hero group companies, including Hero Switzerland and Hero Italy. He served for nine years by the international construction tool manufacturer Hilti and served a number of commercial and finance related positions in various countries. Mr. Gadola served as Vice President of Corporate Audit and Chief Financial Officer of Hilti's Latin American, U.S. and German operations and also served as its Financial Director. He served as an Audit Manager of Sandoz International Ltd. and for Swiss Bank Corporation, Basel, in Corporate Finance. He serves as Chairman of Instradent AG. Mr. Gadola holds a Masters Degree in Business Administration and Economics from the University of Basel (Switzerland) in 1987. He also completed the Accelerated Management Development Program at the London School of Economics and at IMD in Lausanne. He is Director at Mettler-Toledo International Inc. since May 9, 2019.

CEO Compensation
  • Marco's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Marco's remuneration is about average for companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Straumann Holding management team in years:

6.6
Average Tenure
53
Average Age
  • The average tenure for the Straumann Holding management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Marco Gadola

TITLE
CEO & Member of Executive Management Board
COMPENSATION
CHF4M
AGE
56
TENURE
6.6 yrs

Sebastian Burckhardt

TITLE
Secretary of the Board & Director
COMPENSATION
CHF213K
AGE
65

Peter Hackel

TITLE
CFO & Member of Executive Management Board
COMPENSATION
CHF428K
AGE
50
TENURE
4.9 yrs

Wolfgang Becker

TITLE
Head of Distributor & Emerging Markets - EMEA and Member of Executive Management Board
AGE
53
TENURE
6.6 yrs

Frank Hemm

TITLE
Head of Marketing & Education and Member of Executive Management Board
AGE
49
TENURE
7.8 yrs

Guillaume Daniellot

TITLE
Executive VP of Sales - North America & Member of Executive Management Board
AGE
49
TENURE
6.6 yrs

Gerhard Bauer

TITLE
Head of Research
AGE
63
TENURE
6.6 yrs

Petra Rumpf

TITLE
Head of Dental Service Organizations & Member of the Executive Management Board
AGE
52
TENURE
4.7 yrs

Jens Dexheimer

TITLE
Head of Sales - Europe & Member of Executive Management Board
AGE
53
TENURE
3.8 yrs

Matthias Schupp

TITLE
Head of Sales - Latin America & Member of Executive Management Board
AGE
55
TENURE
3.8 yrs
Board of Directors Tenure

Average tenure and age of the Straumann Holding board of directors in years:

9.6
Average Tenure
55.5
Average Age
  • The tenure for the Straumann Holding board of directors is about average.
Board of Directors

Gilbert Achermann

TITLE
Chairman
COMPENSATION
CHF874K
AGE
55
TENURE
9.7 yrs

H. C. Straumann

TITLE
Vice Chairman of the Board
COMPENSATION
CHF320K
AGE
56
TENURE
9.6 yrs

Sebastian Burckhardt

TITLE
Secretary of the Board & Director
COMPENSATION
CHF213K
AGE
65
TENURE
17.8 yrs

Ulrich Looser

TITLE
Non-Executive Director
COMPENSATION
CHF267K
AGE
62
TENURE
9.7 yrs

Beat Lüthi

TITLE
Non-Executive Director
COMPENSATION
CHF267K
AGE
57
TENURE
9.7 yrs

Regula Wallimann

TITLE
Non-Executive Director
COMPENSATION
CHF213K
AGE
52
TENURE
2.6 yrs

Monique Bourquin

TITLE
Non-Executive Director
COMPENSATION
CHF213K
AGE
53
TENURE
2.6 yrs

Juan-José Gonzalez

TITLE
Additional Board Member
AGE
46
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess Straumann Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Straumann Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Should We Expect From Straumann Holding AG's (VTX:STMN) Earnings In The Year Ahead?

See our latest analysis for Straumann Holding Can we expect Straumann Holding to keep growing? … SWX:STMN Past and Future Earnings, September 4th 2019 From the current net income level of CHF273m and the final forecast of CHF482m by 2022, the annual rate of growth for STMN’s earnings is 17%. … Other High-Growth Alternatives : Are there other high-growth stocks you could be holding instead of Straumann Holding?

Simply Wall St -

Despite Its High P/E Ratio, Is Straumann Holding AG (VTX:STMN) Still Undervalued?

View our latest analysis for Straumann Holding How Do I Calculate Straumann Holding's Price To Earnings Ratio? … The formula for price to earnings is: Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS) Or for Straumann Holding: P/E of 41.77 = CHF762.2 ÷ CHF18.25 (Based on the trailing twelve months to June 2019.) Is A High Price-to-Earnings Ratio Good? … The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings.

Simply Wall St -

Should You Worry About Straumann Holding AG's (VTX:STMN) CEO Pay?

View our latest analysis for Straumann Holding How Does Marco Gadola's Compensation Compare With Similar Sized Companies? … At the time of writing our data says that Straumann Holding AG has a market cap of CHF12b, and is paying total annual CEO compensation of CHF3.7m. … The graphic below shows how CEO compensation at Straumann Holding has changed from year to year.

Simply Wall St -

Does Straumann Holding AG's (VTX:STMN) Past Performance Indicate A Weaker Future?

When Straumann Holding AG (VTX:STMN) released its most recent earnings update (31 December 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … Check out our latest analysis for Straumann Holding Commentary On STMN's Past Performance STMN's trailing twelve-month earnings (from 31 December 2018) of CHF273m has declined by -2.4% compared to the previous year. … I suggest you continue to research Straumann Holding to get a better picture of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for STMN’s future growth?

Simply Wall St -

Does The Data Make Straumann Holding AG (VTX:STMN) An Attractive Investment?

Flawless balance sheet with reasonable growth potential STMN is expected to churn out cash in the short term, with its operating cash flow predicted to expand by 57%. … This indicates that STMN has sufficient cash flows and proper cash management in place, which is a crucial insight into the health of the company. … SWX:STMN Historical Debt, August 2nd 2019 Next Steps: For Straumann Holding, there are three key aspects you should further examine: Valuation: What is STMN worth today?

Simply Wall St -

A Closer Look At Straumann Holding AG's (VTX:STMN) Impressive ROE

The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Straumann Holding: 23% = CHF273m ÷ CHF1.2b (Based on the trailing twelve months to December 2018.) Most readers would understand what net profit is, but it’s worth explaining the concept of shareholders’ equity. … Does Straumann Holding Have A Good Return On Equity? … Combining Straumann Holding's Debt And Its 23% Return On Equity Although Straumann Holding does use debt, its debt to equity ratio of 0.17 is still low.

Simply Wall St -

Should You Like Straumann Holding AG’s (VTX:STMN) High Return On Capital Employed?

The formula for calculating the return on capital employed is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) Or for Straumann Holding: 0.22 = CHF351m ÷ (CHF1.9b - CHF272m) (Based on the trailing twelve months to December 2018.) Therefore, Straumann Holding has an ROCE of 22%. … Due to the way ROCE is calculated, a high level of current liabilities makes a company look as though it has less capital employed, and thus can (sometimes unfairly) boost the ROCE. … Our Take On Straumann Holding's ROCE With low current liabilities and a high ROCE, Straumann Holding could be worthy of further investigation.

Simply Wall St -

Should You Buy Straumann Holding AG (VTX:STMN) When Prices Drop?

High quality companies, such as Straumann Holding AG, are impacted by general market panic and sell-off, but the fundamentals of these companies stay the same. … See our latest analysis for Straumann Holding Straumann Holding AG provides tooth replacement solutions worldwide. … This consistent market outperformance illustrates a robust track record of delivering strong returns over a number of years, increasing my conviction in Straumann Holding as an investment over the long run.

Simply Wall St -

Straumann Holding AG (VTX:STMN): Can Growth Justify Its June Share Price?

As Warren Buffett’s right-hand man Charlie Munger said, “No matter how wonderful a business is, it’s not worth an infinite price.” Straumann Holding is available at price-to-earnings ratio of 50.88x, showing us it is overvalued compared to the CH market average ratio of 18.36x , and overvalued based on current earnings compared to the Medical Equipment industry average of 30.89x. … But, since Straumann Holding is a high-growth stock, we must also account for its earnings growth by using calculation called the PEG ratio. … Based on this growth, Straumann Holding's stock can be considered overvalued , based on fundamental analysis.

Simply Wall St -

Calculating The Intrinsic Value Of Straumann Holding AG (VTX:STMN)

Today, we will estimate the stock's intrinsic value by estimating the company's future cash flows and discounting them to their present value. … A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 10-year free cash flow (FCF) estimate 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF (CHF, Millions) CHF256.01 CHF339.50 CHF413.29 CHF515.00 CHF668.00 CHF779.68 CHF878.59 CHF965.24 CHF1.04k CHF1.11k Growth Rate Estimate Source Analyst x8 Analyst x9 Analyst x8 Analyst x2 Analyst x1 Est @ 16.72% Est @ 12.69% Est @ 9.86% Est @ 7.89% Est @ 6.5% Present Value (CHF, Millions) Discounted @ 8.68% CHF235.56 CHF287.42 CHF321.94 CHF369.12 CHF440.53 CHF473.10 CHF490.53 CHF495.85 CHF492.22 CHF482.35 Present Value of 10-year Cash Flow (PVCF)= CHF4.09b "Est" = FCF growth rate estimated by Simply Wall St The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. … In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 8.7%.

Simply Wall St -

Company Info

Description

Straumann Holding AG provides tooth replacement solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, biomaterials, CADCAM prosthetics, digital equipment, software, and clear aligners for applications in replacement, restorative, orthodontic, and preventative dentistry. The company offers dental implant systems, including tissue and bone level implant lines; ceramic, mini, and dental implant systems; and guided surgery and surgical instruments, as well as implant-borne prosthetics, such as tissue and bone level prosthetics. It also provides biomaterials, bone substitutes, membranes, biologics, and soft tissue management and oral healing products; digital solutions for dental labs, dentists, and centralized milling centers, as well as materials, third party systems, and guided surgery; surgical instruments comprising surgical cassettes, guided instruments, implant maintenance products, bone block fixation sets, bonerings, titanium pin sets, and other cassettes; and edentulous, pro arch fixed, prosthetic, and mini implant solutions for edentulous patients. In addition, the company offers esthetic restorations that include ceramic implant monotypes, ceramic implants, abutments, 3D-soft tissue grafts, biologics, and other solutions; Roxolid for use in implant dentistry; SLActive implants; Endogain for wound healing; and short and bone level tapered implants. Further, it provides Neodent systems; Medentika solutions; Equinox dental implant systems; Clear Correct aligners; and training and education services to its customers. The company offers its products to general dentists, specialists, and dental technicians/laboratories, as well as corporate customers, such as dental chains, distributors, hospitals, and university clinics in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

Details
Name: Straumann Holding AG
STMN
Exchange: SWX
Founded: 1954
CHF14,145,596,189
15,833,441
Website: http://www.straumann.com
Address: Straumann Holding AG
Peter Merian-Weg 12,
Basel,
Basel-Stadt, 4002,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX STMN Registered Shares SIX Swiss Exchange CH CHF 02. Jun 1998
OTCPK SAUH.F Registered Shares Pink Sheets LLC US USD 02. Jun 1998
DB QS5 Registered Shares Deutsche Boerse AG DE EUR 02. Jun 1998
LSE 0QMV Registered Shares London Stock Exchange GB CHF 02. Jun 1998
BMV STMN N Registered Shares Bolsa Mexicana de Valores MX MXN 02. Jun 1998
OTCPK SAUH.Y ADR Pink Sheets LLC US USD 10. Dec 2008
Number of employees
Current staff
Staff numbers
6,682
Straumann Holding employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/14 20:41
End of day share price update: 2019/11/13 00:00
Last estimates confirmation: 2019/11/12
Last earnings filing: 2019/08/14
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.